Lamotrigine (LTG), a new generation antiepileptic drug (AED), is approved as adjunctive therapy for partial seizures as well as generalized seizures of Lennox-Gastaut syndrome in adult and pediatric patients aged ≥ 2 years. In addition, the drug is indicated for conversion from enzyme-inducing AED or valproate to monotherapy in adults with partial seizures and is also used for the maintenance treatment of bipolar I disorder [1]. It is also investigated for its use for the treatment of treatment-resistant depressive disorders [2].
16
AGO
AGO
0